Allan P. Pollack
#129,540
Most Influential Person Now
Allan P. Pollack's AcademicInfluence.com Rankings
Allan P. Pollackmedical Degrees
Medical
#2125
World Rank
#2525
Historical Rank
Oncology
#118
World Rank
#122
Historical Rank
Allan P. Pollackphilosophy Degrees
Philosophy
#6239
World Rank
#9241
Historical Rank
Logic
#3423
World Rank
#4578
Historical Rank
Download Badge
Medical Philosophy
Why Is Allan P. Pollack Influential?
(Suggest an Edit or Addition)Allan P. Pollack's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. (2008) (1150)
- Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. (2002) (1096)
- Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. (2007) (868)
- Prostate cancer. Clinical practice guidelines in oncology. (2007) (839)
- Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. (2000) (536)
- Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. (1999) (465)
- Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. (2000) (420)
- Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. (2013) (406)
- Primary treatment of cystosarcoma phyllodes of the breast (2000) (366)
- Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial (2003) (351)
- Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. (2002) (314)
- Bladder cancer. Clinical practice guidelines in oncology. (2005) (278)
- Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. (2006) (270)
- Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. (2016) (266)
- Establishment of two human prostate cancer cell lines derived from a single bone metastasis. (1997) (265)
- Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? (2008) (250)
- Prostate target volume variations during a course of radiotherapy. (1998) (231)
- Prostate cancer early detection. Clinical practice guidelines in oncology. (2010) (226)
- Intrafraction prostate motion during IMRT for prostate cancer. (2001) (224)
- External beam radiotherapy dose response of prostate cancer. (1997) (219)
- Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. (1996) (197)
- Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. (2000) (193)
- Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. (2002) (191)
- What dose of external-beam radiation is high enough for prostate cancer? (2007) (173)
- MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. (2004) (172)
- Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. (1997) (167)
- Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. (1995) (164)
- Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? (2007) (164)
- The role of radiation therapy in the management of dermatofibrosarcoma protuberans. (1998) (162)
- Prognostic factors for clinically localized prostate carcinoma (1997) (160)
- Experience of ultrasound-based daily prostate localization. (2003) (156)
- Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. (2002) (155)
- Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (2004) (153)
- The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer (2008) (148)
- External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. (2000) (147)
- Radiation therapy in the management of desmoid tumors. (1998) (147)
- Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial (2018) (146)
- Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). (2002) (146)
- Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. (1998) (144)
- Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. (1996) (143)
- Hazards of dose escalation in prostate cancer radiotherapy. (2003) (141)
- Patterns of recurrence in extremity liposarcoma (1999) (138)
- Prostate cancer radiotherapy dose response: an update of the fox chase experience. (2004) (138)
- Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer (1994) (134)
- Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. (2017) (133)
- Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. (1997) (131)
- Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O (2005) (128)
- Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. (1998) (124)
- Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. (2005) (118)
- Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy (2004) (114)
- A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. (2004) (114)
- Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. (2001) (112)
- Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. (1997) (112)
- Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. (1996) (111)
- Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. (2001) (111)
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. (2005) (109)
- Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. (1994) (106)
- COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. (2007) (106)
- MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. (2009) (105)
- Prostate cancer radiomics and the promise of radiogenomics. (2016) (103)
- The fall and rise of prostate‐specific antigen: Kinetics of serum prostate‐specific antigen levels after radiation therapy for prostate cancer (1993) (103)
- Molecular markers of outcome after radiotherapy in patients with prostate carcinoma (2003) (103)
- Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. (1994) (96)
- Thymoma: treatment and prognosis. (1992) (95)
- The relationship of local control to distant metastasis in muscle invasive bladder cancer. (1995) (93)
- Thymoma. A retrospective study of 87 cases (1994) (93)
- Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. (1995) (92)
- Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. (2002) (91)
- Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. (2002) (90)
- Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 (2007) (88)
- Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. (1995) (88)
- Radiation therapy dose escalation for prostate cancer: a rationale for IMRT (2003) (87)
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. (1994) (86)
- Dosimetric evaluation of MRI-based treatment planning for prostate cancer (2004) (86)
- The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer (2004) (83)
- Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies (2016) (81)
- Serum testosterone levels after external beam radiation for clinically localized prostate cancer. (1997) (80)
- Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. (2017) (78)
- Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. (2006) (78)
- Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. (1995) (77)
- Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. (2003) (75)
- A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. (2008) (75)
- Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. (1997) (75)
- Lack of prostate cancer radiosensitization by androgen deprivation. (2001) (74)
- Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer. (2004) (72)
- Development of a laser-driven proton accelerator for cancer therapy (2006) (69)
- The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. (1995) (66)
- Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features (2018) (66)
- Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. (2008) (65)
- MDM2 as a predictor of prostate carcinoma outcome (2005) (64)
- Prostate‐specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death (2007) (64)
- Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. (1994) (63)
- Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. (2003) (63)
- Adjuvant radiotherapy for phyllodes tumor of breast. (1998) (62)
- Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer (2011) (62)
- Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. (2000) (62)
- Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. (2005) (61)
- Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. (1998) (60)
- Radiation from tritiated thymidine perturbs the cell cycle progression of stimulated lymphocytes. (1979) (59)
- Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. (2005) (59)
- Radiation dose and late failures in prostate cancer. (2007) (59)
- Deoxyribonucleic acid replication in single cells and chromosomes by immunologic techniques. (1976) (59)
- Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. (2007) (59)
- Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. (2003) (59)
- Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. (1990) (59)
- Frequency and characterization of p53 mutations in clinically localized prostate cancer. (1995) (59)
- The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. (2010) (58)
- Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. (1999) (58)
- Gains from real-time tracking of prostate motion during external beam radiation therapy. (2009) (58)
- A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. (2020) (57)
- Radiotherapy for stage II testicular seminoma. (2001) (57)
- Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. (1997) (57)
- Antisense Bcl‐2 sensitizes prostate cancer cells to radiation (2005) (57)
- Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. (1999) (56)
- Vitamin E succinate inhibits NF‐κB and prevents the development of a metastatic phenotype in prostate cancer cells: Implications for chemoprevention (2007) (56)
- Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. (2003) (56)
- Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. (1996) (56)
- Measurement of cell-cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation. (1988) (56)
- Preoperative radiotherapy for muscle‐invasive bladder carcinoma. Long term follow‐up and prognostic factors for 338 patients (1994) (56)
- Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. (2005) (56)
- Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. (2012) (55)
- Predictive models in external beam radiotherapy for clinically localized prostate cancer (2009) (55)
- Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. (2004) (54)
- External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? (1998) (54)
- The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy (1994) (54)
- Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. (2013) (54)
- Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. (2007) (53)
- Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. (1996) (53)
- NCCN Urothelial Cancer Practice Guidelines (1998) (52)
- Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. (2000) (52)
- The Gleason score shift: score four and seven years ago. (2003) (52)
- Survivin is a potential mediator of prostate cancer metastasis. (2010) (51)
- Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. (2019) (50)
- Timing of biochemical failure and distant metastatic disease for low‐, intermediate‐, and high‐risk prostate cancer after radiotherapy (2007) (50)
- Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. (2003) (49)
- Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. (2003) (49)
- Does treatment duration affect outcome after radiotherapy for prostate cancer? (2008) (48)
- Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. (2003) (48)
- Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer (2021) (48)
- Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. (1994) (47)
- Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. (2003) (47)
- Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. (1995) (47)
- Relationship of Ki‐67 labeling index to DNA‐ploidy, S‐phase fraction, and outcome in prostate cancer treated with radiotherapy (1999) (46)
- Quantitation of cell kinetic responses using simultaneous flow cytometric measurements of DNA and nuclear protein. (1984) (46)
- Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate (2007) (46)
- Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. (1995) (46)
- Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs. (2007) (45)
- Rectal dose variation during the course of image-guided radiation therapy of prostate cancer. (2010) (45)
- Parameters for treatment decisions for salvage radiation therapy. (2005) (45)
- Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. (2007) (44)
- Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation (1997) (44)
- On Modern Technical Approaches of Three- Dimensional High-Dose Lattice Radiotherapy (LRT) (2010) (42)
- Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. (2002) (42)
- Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. (2006) (41)
- Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. (2003) (41)
- Treatment planning using a dose-volume feasibility search algorithm. (2001) (40)
- The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial (2022) (40)
- Flow cytometric analysis of RNA content in different cell populations using pyronin Y and methyl green. (1982) (40)
- The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. (2021) (39)
- Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. (2016) (39)
- Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. (2015) (38)
- Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. (1997) (38)
- Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. (2004) (38)
- Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. (2003) (38)
- A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate. (2003) (37)
- Delineation of Tumor Habitats based on Dynamic Contrast Enhanced MRI (2017) (37)
- Quiescence in R3327-G rat prostate tumors after androgen ablation. (1997) (36)
- Target localization for post‐prostatectomy patients using CT and ultrasound image guidance (2005) (35)
- Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer (2018) (34)
- 4 Preliminary results of a randomized dose-escalation study comparing 70 GY to 78 GY for the treatment of prostate cancer (1999) (33)
- Comparing computed tomography localization with daily ultrasound during image‐guided radiation therapy for the treatment of prostate cancer: a prospective evaluation (2007) (33)
- Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. (2007) (33)
- Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: The moderating role of age (2008) (33)
- Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. (2005) (33)
- Biomarkers associated with prostate cancer progression. (1994) (32)
- Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. (2008) (32)
- Daily target localization for prostate patients based on 3D image correlation. (2004) (32)
- Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. (2007) (31)
- Stereotactic IMRT for prostate cancer: Dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT (2004) (31)
- Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. (1994) (30)
- NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. (1998) (30)
- Locally recurrent soft tissue sarcoma of the extremities. (1998) (30)
- Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? (2002) (30)
- Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors. (1982) (30)
- Bladder cancer. Clinical guidelines in oncology. (2006) (30)
- Radiotherapy for regionally localized hormone refractory prostate cancer. (1995) (30)
- Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. (1998) (29)
- Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? (2005) (29)
- Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. (2002) (29)
- The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. (2004) (29)
- Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. (1999) (28)
- Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry. (2000) (28)
- Clinical staging of prostate cancer: Reproducibility and clarification of issues (2001) (27)
- The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. (2000) (27)
- Segmentation of prostate and prostate zones using deep learning (2020) (27)
- Classification of suspicious lesions on prostate multiparametric MRI using machine learning (2018) (27)
- Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? (1998) (27)
- Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy (1999) (26)
- Near‐diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy (1994) (26)
- The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02 (2009) (26)
- Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. (2005) (25)
- Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. (2003) (25)
- A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. (2013) (25)
- A collaboratory for radiation therapy treatment planning optimization research (2006) (25)
- Prevalence and patterns of self‐initiated nutritional supplementation in men at high risk of prostate cancer (2004) (25)
- Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy (2018) (24)
- Evaluation of nuclear factor κB and chemokine receptor CXCR4 co‐expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610 (2011) (23)
- Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo (2008) (23)
- The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M? (1995) (23)
- Noninvasive Real-time Prostate Tracking Using a Transperineal Ultrasound Approach (2012) (23)
- Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. (1999) (22)
- MR-guided focused ultrasound: enhancement of intratumoral uptake of [3H]-docetaxel in vivo (2010) (22)
- The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. (1994) (22)
- Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. (2017) (22)
- PKA knockdown enhances cell killing in response to radiation and androgen deprivation (2011) (22)
- Cell kinetic effects of incorporated 3H-thymidine on proliferating human lymphocytes: flow cytometric analysis using the DNA/nuclear protein method. (1985) (22)
- Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer. (2004) (21)
- The significance of DNA‐ploidy and S‐phase fraction in node‐positive (stage D1) prostate cancer treated with androgen ablation (1997) (21)
- Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. (2002) (21)
- Influence of Number of CAG Repeats on Local Control in the RTOG 86-10 Protocol (2006) (21)
- Postprostatectomy radiation therapy for prostate cancer. (2008) (20)
- In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy. (1983) (20)
- Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. (2009) (19)
- Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors (2018) (19)
- Flow cytometric analysis of two incorporated halogenated thymidine analogues and DNA in a mouse mammary tumor grown in vivo. (1993) (19)
- Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer. (2020) (19)
- Optical molecular imaging‐guided radiation therapy part 1: Integrated x‐ray and bioluminescence tomography (2017) (19)
- Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. (2002) (19)
- Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy (1996) (18)
- Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial (2009) (18)
- Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. (2005) (18)
- Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610 (2003) (18)
- The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment. (1994) (18)
- ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. (2009) (18)
- The role of radiomics in prostate cancer radiotherapy (2020) (18)
- Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. (2016) (18)
- Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. (2007) (18)
- Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. (2008) (16)
- The kinetics of the formation of a G2 block from tritiated thymidine in phytohemagglutinin-stimulated human lymphocytes. (1980) (16)
- Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. (1997) (16)
- Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. (2006) (16)
- The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. (2007) (16)
- The prognostic significance of flow cytometric DNA analysis (1992) (16)
- PHASE i TRIAL OF MRI-GUIDED Prostate Cancer Lattice Extreme Ablative Dose (LEAD) BOOST Radiotherapy. (2020) (15)
- MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL (2019) (15)
- MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment (2012) (15)
- An image guided small animal stereotactic radiotherapy system (2016) (15)
- Optical molecular imaging‐guided radiation therapy part 2: Integrated x‐ray and fluorescence molecular tomography (2017) (15)
- A Prostate Specific Antigen (PSA) Bounce Greater Than 1.4 ng/mL Is Clinically Significant After External Beam Radiotherapy for Prostate Cancer (2006) (15)
- Differences in flow cytometry and 3H-thymidine analyses of perturbed human lymphocytes. (1979) (15)
- Radical Prostatectomy Findings in White Hispanic/Latino Men With NCCN Very Low-risk Prostate Cancer Detected by Template Biopsy (2016) (15)
- Positive prostate biopsy laterality and implications for staging. (2003) (14)
- Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. (2017) (14)
- Preliminary report of toxicity following 3D Conformal Radiation Therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) (2001) (14)
- Flow cytometric analysis of the response of the r3327‐g rat prostatic adenocarcinoma to endocrine manipulation (1981) (14)
- Is intraoperative nomogram-based overplanning of prostate implants necessary? (2003) (14)
- Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. (2015) (14)
- The impact of dose‐escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms (2013) (14)
- 4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models. (2016) (14)
- Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo. (2011) (13)
- Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation. (1985) (13)
- Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study (2017) (13)
- Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA). (2021) (13)
- Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study (2018) (13)
- A Tissue Biomarker–Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02 (2014) (13)
- Bioluminescence Tomography Guided Small-Animal Radiation Therapy and Tumor Response Assessment. (2018) (12)
- Treatment of prostate cancer with regional lymph node (N1) metastasis. (2003) (12)
- Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification (2017) (12)
- Calculating potential doubling time using monoclonal antibodies specific for two halogenated thymidine analogues. (1993) (12)
- Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance (2015) (12)
- An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. (2017) (12)
- Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. (1997) (11)
- Flow cytometric monitoring of R 3327 rat prostate carcinoma. (1981) (11)
- Prostate cancer gene therapy and the role of radiation. (2002) (11)
- Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation (2008) (11)
- Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. (1998) (11)
- Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity (2016) (11)
- 2209: Intensity Modulated Radiation Therapy for Prostate Cancer: Preliminary Results on Treatment Morbidity Compared to 3-D Conformal Radiation Therapy (2006) (11)
- Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer. (2016) (10)
- Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer (2012) (10)
- Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. (2004) (10)
- A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer. (2003) (10)
- Flow cytometric analysis of DNA and nuclear protein in paraffin-embedded tissue. (1993) (10)
- 15 : Long-Term Results of a Randomized Dose Escalation Trial for Prostate Cancer (2006) (10)
- A Matched Pair Comparison of Intensity Modulated Radiotherapy and Three-dimensional Conformal Radiotherapy for Prostate Cancer: Toxicity and Outcomes (2007) (10)
- Flow cytometric cell-kinetic analysis by simultaneously staining nuclei with propidium iodide and fluorescein isothiocyanate. (1990) (10)
- Validation of a deformable MRI to CT registration algorithm employing same day planning MRI for surrogate analysis (2018) (10)
- SU-F-J-171: Robust Atlas Based Segmentation of the Prostate and Peripheral Zone Regions On MRI Utilizing Multiple MRI System Vendors. (2016) (10)
- Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness (2017) (10)
- Developing a radiation error scoring system to monitor quality control events in a radiation oncology department. (2009) (10)
- Simultaneous cytokinetic measurement of aneuploid tumors and associated diploid cells following continuous labelling with chlorodeoxyuridine. (1994) (9)
- The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis. (2018) (9)
- In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns: a preliminary report. (1986) (9)
- Erratum: Lack of prostate cancer radiosensitization by androgen deprivation (International Journal of Radiation Oncology Biology Physics (2001) 51 (1002-1007)) (2002) (9)
- Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier (2020) (9)
- Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer. (2016) (9)
- Does age matter in the selection of treatment for men with early‐stage prostate cancer? (2006) (9)
- Entering an era of radiogenomics in prostate cancer risk stratification (2018) (9)
- Plasmonic Optical Imaging of Gold Nanorods Localization in Small Animals (2018) (9)
- Cell kinetic perturbations after irradiation and caffeine in the BG-1 ovarian carcinoma cell line. (1991) (9)
- The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer. (2006) (8)
- Flow Cytometric Analysis of Cell Kinetic Responses Using Measurements of Correlated DNA and Nuclear Protein a (1986) (8)
- Automatic Detection of Prostate Tumor Habitats using Diffusion MRI (2018) (8)
- Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation (2004) (8)
- In vivo cell kinetic effects of cis-platinum on human ovarian cancer xenografts measured by dual parameter flow cytometry. (1987) (8)
- 2281 : Statin Use Prior to Radiation Therapy for Prostate Cancer Does Not Improve Outcome: The Fox Chase Experience (2006) (8)
- Contemporary role of postoperative radiotherapy for prostate cancer (2018) (8)
- Flow Cytometric Analysis of R3327 Rat Prostate Adenocarcinoma Grown In Vivo and In Vitro (1982) (8)
- Specific staining of iododeoxyuridine and bromodeoxyuridine in tumors double labelled in vivo: a cell kinetic analysis. (1995) (8)
- Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 (2000) (8)
- Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses (2020) (8)
- Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. (2003) (7)
- Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02 (2003) (7)
- Towards a universal MRI atlas of the prostate and prostate zones (2018) (7)
- Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. (2020) (7)
- On Modern Technical Approaches of 3D High-dose Lattice Radiotherapy (LRT) (2009) (7)
- The temporal kinetics of PSA after 3D-conformal radiotherapy with androgen deprivation (2003) (7)
- Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial (2010) (6)
- Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy Versus Moderate Hypofractionation for Clinically Localized Prostate Cancer (2016) (6)
- Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. (2021) (6)
- Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer (2017) (6)
- Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. (2003) (6)
- The effect of sequencing of androgen ablation and radiation on prostate cancer growth (2002) (6)
- Recognition and reduction of artifacts from autolysis in paraffin-embedded tissue using DNA/nuclear protein flow cytometry. (1993) (6)
- Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. (2022) (6)
- Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive and androgen-insensitive prostate cancer cells to radiation (Molecular Cancer Research (2008) 6, (1742-1754)) (2008) (6)
- Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (6)
- Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. (2021) (6)
- Prostate Cancer-Specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy. (2016) (6)
- Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis. (2015) (6)
- Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. (2006) (6)
- Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. (2017) (6)
- Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy (2003) (6)
- Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk (2009) (6)
- 139 Predictors of distant metastasis 7 years after a rising PSA in prostate cancer patients treated with external beam radiotherapy (1999) (5)
- Comparison of 3d conformal and intensity-modulated radiation therapy for early-stage prostate cancer (2001) (5)
- Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer. (2012) (5)
- Radiation Therapy for High Risk Prostate Cancer: Do Patients 70 Years or Older Benefit from Combined Androgen Deprivation Therapy? (2008) (5)
- How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? (2008) (5)
- Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. (2007) (5)
- Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. (1994) (5)
- Intensity modulated radiation therapy (IMRT) is a cost-effective treatment for intermediate risk prostate cancer (2004) (5)
- Noninvasive Real-Time Prostate Tracking Using a Transperineal Ultrasound: A Clinical Trial Comparison to RF Transponders With Visual Confirmation (2013) (5)
- Does backdating change outcome when the ASTRO definition of biochemical control is used in patients with clinically localized prostate cancer treated with 3D conformal radiation therapy alone (2002) (5)
- Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial (2011) (5)
- In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. (2004) (5)
- 47 Complications from dose escalation in prostate cancer: Preliminary results of a randomized trial (1999) (5)
- Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. (2020) (5)
- Assessment of specific versus combined purpose knowledge based models in prostate radiotherapy (2018) (5)
- Proliferation kinetics of recruited cells in a mouse mammary carcinoma. (1994) (5)
- Influence of number of CAG repeats on local control in the RTOG 86–10 protocol (2004) (5)
- 1192: A Nomogram to Predict the Outcome of Salvage Radiotherapy (RT) for Biochemical Recurrence (BCR) Following Radical Prostatectomy (RP) (2006) (5)
- Repeatability of CBCT Radiomic Features and Their Correlation to CT Radiomic Features for Prostate Cancer. (2021) (5)
- Prostate cancer: Moderate hypofractionated radiotherapy — not yet a standard of care (2016) (5)
- Immunocompromised Patients With Prostate Cancer Treated With External Beam Radiation: A Matched Pair Analysis (2015) (5)
- Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. (2000) (5)
- Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth. (1984) (5)
- Clinical Experience on Localization and Real-Time Tracking of the Prostate During External Radiotherapy using Calypso® 4D Localization System (2007) (5)
- Predicting Local Persistence of Intermediate and High-risk Prostate Cancer using Percentage of Adenocarcinoma in Pretreatment Biopsy Tissue (2008) (4)
- What pretreatment prostate-specific antigen level warrants long-term androgen deprivation? (2005) (4)
- Double labelling to obtain S phase subpopulations: application to determine cell kinetics of diploid cells in an aneuploid tumour (1994) (4)
- A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients. (2015) (4)
- 2056 Adjuvant radiotherapy for phyllodes tumor of the breast (1997) (4)
- Reconstruction of X-Ray Fluorescence Computed Tomography From Sparse-View Projections via L1-Norm Regularized EM Algorithm (2020) (4)
- Clinicogenomic characterization of prostate cancer liver metastases (2022) (4)
- TU-CD-BRA-04: Evaluation of An Atlas-Based Segmentation Method for Prostate and Peripheral Zone Regions On MRI (2015) (4)
- Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy (2016) (4)
- Calculating potential doubling time (Tpot) using monoclonal antibodies specific for two halogenated thymidine analogues. Supported by an ASTRO Research Fellowship 1991–1992 (1992) (4)
- Evaluation of ultrasound-based daily prostate localization during IMRT for prostate cancer (2001) (4)
- Relationship of prostate biopsy status to radiotherapy dose, PSA nadir level and outcome in participants of a randomized dose escalation trial for prostate cancer (2001) (4)
- Reply to M.J. Brenner et al and I.R. Vogelius et al. (2014) (4)
- Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement (2003) (4)
- Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk. (2017) (4)
- Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. (2018) (4)
- Abstract17: Increasing Radiotherapy Dose for Prostate Cancer Reduces a Late Wave of Distant Metastasis (2006) (4)
- Using radiogenomics to characterize MRI-guided prostate cancer biopsy heterogenity. (2015) (4)
- Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. (2000) (4)
- Short term androgen deprivation and PSA doubling time: their relationship to one another and to disease progression following radiation therapy for prostate cancer (2002) (4)
- 66 Supra-additive apoptotic response in predominantly quiescent prostate tumors when treated with androgen ablation and radiotherapy (1996) (4)
- Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. (2000) (4)
- Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer? (2008) (4)
- Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer? (2005) (4)
- Prostate-specific antigen: A prognostic factor and outcome marker for prostate cancer treated with radiation therapy (1994) (3)
- Observations of Prostate Intrafractional Motion during External Beam Radiation Therapy (2009) (3)
- Nsaid use confers a survival advantage for prostate cancer patients treated with radiation therapy (2004) (3)
- Anterior or Posterior Prostate Cancer Tumor Nodule Location Predicts Likelihood of Certain Adverse Outcomes at Radical Prostatectomy. (2021) (3)
- Flow cytometric analysis of R3327 rat prostate adenocarcinoma grown in vivo and in vitro. (1983) (3)
- Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (3)
- Delineation and visualization of prostate cancer in multiparametric MRI. (2013) (3)
- The Uncertainties in Target Localization for Prostate and Prostate-bed Radiotherapy with Calypso 4D (2009) (3)
- 1133 : The Nadir+2 Definition of Biochemical Failure Predicts for Overall Survival (2006) (3)
- Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials. (2022) (3)
- Using a dose-volume feasibility search algorithm for radiation treatment planning (2000) (3)
- Prostate cancer: Defining biochemical failure in patients treated with HIFU (2010) (3)
- A Phase 3 Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiation Therapy Postprostatectomy: The MAPS Trial, An Initial Dosimetric Assessment (2014) (3)
- Monte carlo verification of MR-based treatment planning for intensity modulated radiation therapy (2002) (3)
- Noninvasive assessment of radiation-induced renal injury in mice (2021) (3)
- Quantifying Radiosensitization of PSMA-Targeted Gold Nanoparticles on Prostate Cancer Cells at Megavoltage Radiation Energies by Monte Carlo Simulation and Local Effect Model (2022) (3)
- Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial (2012) (3)
- Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. (2021) (3)
- Desmoid tumor outcome following radiation therapy with and without surgical resection (1998) (3)
- Flow Cytometric Analysis of the Response of the R3327-G Rat Prostatic Adenocarcinoma to Endocrine Manipulation (1982) (3)
- Enhancement of Drug Delivery in Prostate Tumor in vivo Using MR Guided Focused Ultrasound (MRgHIFU) (2009) (3)
- DCE-MRI for Delineation of Hypoxic Regions in Prostate Tumors (2010) (3)
- In Vivo Visualization of Metastatic Prostate Cancer (2003) (3)
- Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
- Androgen-ablated node-positive prostate cancer: The case for radiotherapy-In response to Drs. Wiegel and Bressel (1995) (2)
- Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer. (2022) (2)
- Dose-volume histogram analysis does not completely predict the incidence of late effects of radiation in prostate cancer (2004) (2)
- 10-Year Update of a Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer (2018) (2)
- SU-F-BRF-10: Deformable MRI to CT Validation Employing Same Day Planning MRI for Surrogate Analysis. (2014) (2)
- Antisense to Bcl-2 (Genasense™) sensitizes prostate cancer cells to radiation (2004) (2)
- Heterogeneity in Genomic Risk Assessment From Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of MRI Targeted Biopsy. (2020) (2)
- Tumor Resistance to Apoptosis (2004) (2)
- Appropriate Management of Drug Interactions Results in Safe Use of Hepatitis C Therapies in Heart Transplant Recipients (2019) (2)
- Dose-Volume Determinants of Late Genitourinary Toxicity After External Beam Radiotherapy for Prostate Cancer (2005) (2)
- A personalized decision aid for prostate cancer shared decision making (2021) (2)
- TH-C-M100J-09: MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS-MDM2 in Vivo (2007) (2)
- Radiotherapy vs. surgery for prostate cancer: an age old question. (1996) (2)
- Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy (2021) (2)
- Multiparametric Evaluation of Preoperative MRI in Early-Stage Breast Cancer: Prognostic Impact of Peritumoral Fat (2015) (2)
- Oral Scientific SessionsDevelopment and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk (2017) (2)
- The Prognostic Value of p16 Expression in Locally Advanced Prostate Cancer: A Study Based on RTOG 92-02 (2005) (2)
- Post-treatment PSA values within 6 months of 3d conformal radiotherapy for prostate cancer predict for distant metastases (2004) (2)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
- Quantification of the margin required for treating intraprostatic lesions. (2016) (2)
- Protein Kinase A RI-alpha (PKA) Predicts Prostate Cancer Outcome: An Analysis of Radiation Therapy Oncology Group Trial 86-10 (2009) (2)
- Does Total Treatment Duration Affect Outcome in Prostate Cancer Treated With Radiotherapy (2007) (2)
- SU‐FF‐T‐472: Quality Assurance for MR Guided Focused Ultrasound as a Multi‐Modality Platform for Cancer Therapy (2009) (2)
- A Model for Distant Metastasis Incorporating Tissue Biomarkers from Prostate Cancer Patients in Radiation Therapy Oncology Group (RTOG) 92-02 (2008) (2)
- Pretreatment risk stratification of prostate cancer with percent positive prostate biopsy tissue obviates the need for clinical staging and identifies high grade disease suitable for treatment without androgen deprivation (2004) (1)
- MDM2 Expression Is Independent of P53 and Ki-67 in Predicting Prostate Cancer Outcome: An Analysis of RTOG 92-02 (2005) (1)
- MRI Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department (2014) (1)
- Molecular markers of patient outcome in prostate cancer treated with radiotherapy: Ki-67, Bcl-2, Bax, and Bcl-x (2001) (1)
- Boosted Radiation Bystander Effect of PSMA-Targeted Gold Nanoparticles in Prostate Cancer Radiosensitization (2022) (1)
- 2194 : Smoking and its Relationship to GU and GI Toxicity in Prostate Cancer Patients Treated With Radiation (2006) (1)
- Advanced prostate cancer and postoperative radiotherapy. (2007) (1)
- Soft tissue sarcomas treated with external beam radiation therapy with and without the addition of low dose rate brachytherapy (2002) (1)
- Experimental Support for the Possibility of Retrograde Genesis of Intraductal Carcinoma of the Prostate (2022) (1)
- Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers (2021) (1)
- Twenty-five percent positive biopsy rate in a high risk prostate cancer screening program with a PSA ≤ 2.5 ng/ml. (2005) (1)
- Prostate Cancer Phase 1 Lattice Extreme Ablative Dose (LEAD) Trial: Feasibility and Acute Toxicity (2014) (1)
- Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease. (2000) (1)
- Androgen suppression plus radiation therapy for prostate cancer. (2004) (1)
- Image Guided Adaptive Radiotherapy of Prostate Cancer: A Retrospective Study (2008) (1)
- Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial (2016) (1)
- Early Toxicity and Patient Reported Outcomes from a Radiation Hypofractionation Randomized Trial of Extended vs Accelerated Therapy for Prostate Cancer (HEAT) (2018) (1)
- 2224: Prostate Specific Antigen Kinetics in Men Treated With Radiotherapy and Androgen Deprivation (2006) (1)
- Quality Adjusted Survival Comparing Standard Versus Hypofractionated Radiation Therapy in the Treatment of Prostate Cancer (2015) (1)
- Pretreatment serum testosterone as a prognostic factor in patients with node positive prostate cancer treated with androgen ablation (1998) (1)
- Pelvic lymphatic coverage in the treatment of prostate cancer with intensity modulated radiation therapy: A feasibility study (2004) (1)
- Improved target coverage and rectal sparing for treatment of prostate cancer using IMRT vs 3D CRT (2002) (1)
- Contemporary Update of a Multi-institutional Predictive Nomogram for Salvage Radiation Therapy After Prostatectomy (2015) (1)
- Radioprotection by Antagonists of Growth Hormone Releasing Hormone during Whole Body Radiation is Dependent on the Radiation Dose (2009) (1)
- A Software Platform for Rapid Translation of Functional MRI Findings to Radiation Treatment Planning for Prostate Cancer (2011) (1)
- Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. (2004) (1)
- 1124 : Cox-2 Overexpression Predicts Prostate Cancer Outcome: An Analysis of RTOG 92-02 (2006) (1)
- 2244 : Adjusted Radiotherapy Dose Response Curves Following Treatment for Prostate Cancer: Biochemical Failure And Distant Metastasis (2006) (1)
- Radiotherapy: Encouraging early data for SBRT in prostate cancer (2009) (1)
- Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy (2019) (1)
- The Effects of Androgen-Deprivation Therapy on MRI Delta Radiomics Features in a Prospective Radiotherapy Treatment Trial for Prostate Cancer (2020) (1)
- 2198 : Protein Kinase a Antisense Induces Apoptosis and Sensitizes Prostate Tumors to Androgen Deprivation and Radiation In Vivo (2006) (1)
- In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns (1984) (1)
- Genitourinary cancer committee (2001) (1)
- Is pretreatment PSA velocity associated with prostate-cancer-specific mortality rate after radiotherapy? (2006) (1)
- Identification of groups at risk for distant metastasis and death in men with a rising PSA after radiotherapy for prostate cancer (2004) (1)
- Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial (2011) (1)
- Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (1)
- A Comparison of Sexual Function Following Radiotherapy for Prostate Cancer: Results of a Prospective, Randomized Trial of Hypofractionated Intensity Modulated Radiotherapy (2007) (1)
- Treatment planning optimization based on response-surface modeling of cost function versus multiple constraints (2000) (1)
- Abstract1123: Bcl-2 and Bax Predict Prostate Cancer Outcome in Men Treated With Androgen Deprivation and Radiotherapy on RTOG 92-02 (2006) (1)
- Early Changes in Circulating Tumor Cells and Free Circulating DNA in Men Treated for Prostate Cancer: Contrasting Primary Versus Salvage Treatment (2015) (1)
- Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610 (2013) (1)
- Quantification of the margin required for treating intraprostatic lesions (2016) (1)
- 2019 Radiation therapy alone is not successful as salvage treatment for locally recurrent prostate cancer after radical, prostatectomy (1995) (1)
- Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy (2022) (1)
- A SEER Survival Analysis of High Grade Prostate Cancer: Surgery vs. Radiotherapy (2010) (1)
- SU-E-J-218: Novel Validation Paradigm of MRI to CT Deformation of Prostate (2015) (1)
- Hypofractionated radiotherapy for prostate cancer: has the time come? (2012) (1)
- Radiation for prostate cancer issue (2003) (1)
- TU‐CD‐BRB‐12: Radiogenomics of MRI‐Guided Prostate Cancer Biopsy Habitats (2015) (1)
- Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. (2017) (1)
- Ki-67 Staining is a Strong Predictor of Patient Outcomes for Prostate Cancer Patients Treated on RTOG 94-08 (2011) (1)
- Radiotherapy Dose and Late Failures in Prostate Cancer (2007) (1)
- Post-Treatment Biopsy Positivity In Prostate Cancer Patients Undergoing MpMRI-Targeted Radiation Dose Escalation (2020) (1)
- 2280 : Prostate Tumor Biomarker Stability in Archival Tissue From Men Treated With Radiotherapy: An Analysis Of RTOG 92–02 and Fox Chase Randomized Trials (2006) (1)
- 1132 : The Prostate Specific Antigen Velocity Is Unaltered by Radiotherapy Alone When 2 ng/mL per Year or Greater: Distant Metastasis Are the Cause (2006) (1)
- Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier (2020) (1)
- Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer. (2022) (1)
- Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). (2021) (1)
- Biopsy positivity in prostate cancer patients undergoing mpMRI-targeted radiation dose escalation. (2020) (1)
- A comparison of the single vs. double high-risk factor stratification systems for prostate cancer treated radiotherapy without androgen deprivation (2003) (1)
- Prostate cancer treated with radiotherapy with or without androgen deprivation: The importance of the PSA nadir within 12 months. (2004) (1)
- Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection. (2019) (1)
- Benefit of Elective Nodal Irradiation and Androgen Deprivation Therapy with Postprostatectomy Salvage Radiation Therapy for Prostate Cancer (2016) (0)
- Ex-vivo quantification and localization of PSMA-targeted GNPs via x-ray fluorescence imaging (2022) (0)
- Theranostic PSMA-Targeted Gold Nanoparticles using X-ray Fluorescence Imaging Guided Prostate Tumor Radiotherapy (2020) (0)
- Cone-beam x-ray fluorescence imaging using pixelated cadmium telluride photon-counting detector with pinhole collimator (2022) (0)
- 808: Inhibition of NF-kB in Prostate Cancer Cells by Vitamin E Succinate (VES) Decreases Metastatic Potential by Altering Expression of Pro-Metastatic Molecules and Decreasing Cell Invasiveness and Adhesion (2006) (0)
- Does a delay in initiation of external beam radiation therapy after tissue diagnosis effect outcome for men with prostate cancer (2004) (0)
- Post-radiotherapy PSA nadir remains highly predictive of outcome in men who are biochemically free of disease at 1.5 years post-treatment (2003) (0)
- Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis. (2018) (0)
- Is there a role for digital rectal examination in the follow-up of patients with prostate cancer treated with radiotherapy in the PSA era (2004) (0)
- Dual fluorescent molecular substrates selectively report the activation, sustainability and reversibility of cellular PKB/Akt activity (2022) (0)
- TH-EF-207A-07: An Integrated X-Ray/bioluminescence Tomography System for Radiation Guidance and Tumor Evaluation. (2016) (0)
- MO-E-AUD C-04: MR Guided Focused Ultrasound (MRgFU) for Treatment of Prostate Cancer: Feasibility Study of Incresing Intratumoral Uptake of Docetaxel in Vivo (2008) (0)
- Men with Intermediate Risk Prostate Cancer with a History of Transurethral Resection of Prostate (TURP) have a Higher Risk of Biochemical Failure (2005) (0)
- Effect of Target Smoothness on Treatment Planning for Prostate IMRT (2007) (0)
- A New Approach for Tracking Central and Peripheral Lung Tumors without Fiducials (2010) (0)
- Neoadjuvant Radiation Therapy Improves Survival in Patients With T2b/T3 Invasive Bladder Cancer (2013) (0)
- 2021 Prognostic value of P53 in patients with muscle-invasive bladder cancer treated with preoperative radiotherapy (1995) (0)
- Integrated clinicopathologic and molecular risk stratification for disease recurrence in muscle-invasive bladder cancer. (2021) (0)
- 2130 Family history in prostate cancer: Outcome analysis of hereditary versus familial prostate cancer following definitive radiation therapy (1999) (0)
- SMPDL3b modulates radiation‐induced DNA damage response in renal podocytes (2022) (0)
- AKT in Differential miRNA Processing in Prostate Carcinoma (2013) (0)
- Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer (2011) (0)
- Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study (2018) (0)
- Multi-modality X-ray/Optical Tomographic Imaging Guided Radiotherapy Research Platform: In Vivo Optical Background Subtraction for Sensitive Tumor Detection (2020) (0)
- Is it better to use radiation as a salvage therapy than as an adjuvant therapy after radical prostatectomy (2005) (0)
- Genomic Heterogeneity in Prognostic Signatures from Prostate Biopsies: Results from Two Prospective Trials (2020) (0)
- Studies of DNA synthesis in single cells and chromosomes by immunological methodology (1975) (0)
- ADJUVANT RADIATION THERAPY FOR PATHOLOGICALLY ADVANCED PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: A MULTI-INSTITUTIONAL ANALYSIS (2008) (0)
- 1-0083 TITLE : Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation via Manipulation of the MDM 2 Pathway (0)
- MP62-19 THE PERFORMANCE OF MPMRI AND THE 4KSCORE FOR PREDICTING PROGRESSION ON ACTIVE SURVEILLANCE: RESULTS FROM A SINGLE INSTITUTION PROSPECTIVE STUDY (2021) (0)
- 2242 3D- conformal prostate radiotherapy: Minimizing the rectal dose by constrained simulated annealing (1996) (0)
- Adenoviral-E2F1 in Combination with Androgen Deprivation and Radiation Inhibit Prostate Tumor Growth in Nude Mice (2008) (0)
- SU-F-R-25: Automatic Identification of Suspicious Recurrent/residual Disease Regions After Prostatectomy. (2016) (0)
- Comment on: Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Authors' reply (2003) (0)
- The Percentage of Positive Cores Is Not an Appropriate Risk Factor for Prostate Radiotherapy to ≥72 Gy (2005) (0)
- Department of Error (2022) (0)
- (OA20) Association of Circulating Tumor Cells (CTCS) and Genomic Signatures in Prostate Cancer Patients (2018) (0)
- SU-E-T-448: Heightened Apical Positivity of 2-Year Post-Radiotherapy Biopsies Is Not Related to Suboptimal Dosimetry (2015) (0)
- Phospho-AKT Expression and Prognosis of Locally Advanced Prostate Cancer: A Study Based on RTOG 8610 (2005) (0)
- 1456: Recursive Partitioning Analysis of Predictors of Distant Metastasis for Men with Prostate Cancer Treated with Radiotherapy and Androgen Deprivation on RTOG 9202: The Impact of KI-67 (2004) (0)
- Primary Prostate Radiation Therapy: Where Are We Failing? (2012) (0)
- Truncated E2F1 Radiosensitizes Prostate Cancer Cells by Inhibiting The E3 Ubiquitin Ligase SKP2 (2010) (0)
- PCN21: DIFFERENCES IN HUSBAND/WIFE PREFERENCES AND UTILITIES FOR PROSTATE CANCER THERAPIES (2003) (0)
- A Murine Model Of Kidney Injury: The role of SMPDL3b In Radiation And Cisplatin-Induced Nephrotoxicity (2020) (0)
- TU‐C‐ValB‐10: Rectal Dose Variation in Image Guided Radiation Therapy of Prostate Cancer (2006) (0)
- Biopsy Positivity in Prostate Cancer Patients Undergoing MpMRI-Targeted Radiation Dose Escalation (2020) (0)
- Abstract 824: Reduction in prostate tumor growth and induction of anti-tumor immunity after combined treatment with oncolytic VSV and radiation (2017) (0)
- Predictors of Hormone Refractory Disease in Men Treated with Salvage Androgen Deprivation Following Definitive Radiotherapy for Prostate Cancer (2005) (0)
- Adenoviral-mediated p53 transgene expression sensitizes both wild-type and mutant p53 prostate cancer cells to irradiation (1998) (0)
- Erectile Tissue Quantitative DCE-MRI Parameters and Sexual Function Before and After Radiation Therapy in Men With Prostate Cancer (2015) (0)
- PO-1580: CBCT-Based Radiomics of Prostate Cancer (2020) (0)
- Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofrac (2011) (0)
- Abstract 5362: Analysis of circulating tumor cells from prostate cancer patients (2020) (0)
- HIDRATE PRO – Interim Analysis of a Prospective Feasibility Trial Using a Digital Behavioral Intervention to Improve Bladder Filling Compliance in Prostate Cancer Patients Undergoing Radiotherapy (2022) (0)
- MO-D-BRA-02: Application of Hypofractionation in the Prostate (2007) (0)
- SU-F-BRD-06: Dosimetric Cost of a GTV Margin for Simultaneous Integrated Intra- Prostatic Boost Treatments. (2014) (0)
- Dose Escalation Using Conventional Versus IMRT Planning for Hypofractionated Radiation of Lumbosacral Metastases (2014) (0)
- Evaluation of PSMA-Targeted Theranostic Gold Nanoparticles for Prostate Cancer Imaging and Radiosensitization (2020) (0)
- Outcome analysis of prostate cancer patients treated with observation (2002) (0)
- COMMENTARY ON DOSE ESCALATION AND BIOCHEMICAL FAILURE IN PROSTATE CANCER : IN REGARD TO EADE ETAL. Authors' reply (2008) (0)
- Is nomogram-based intraoperative overplanning of I-125 prostate implants necessary (2001) (0)
- The in vivo selection of hormone-independent cells in R3327-G rat prostate tumours (1982) (0)
- Automatic Detection of the Foci of Residual or Recurrent Disease in the Prostate Bed After Prostectomy Using Dynamic Contrast Enhanced-MRI (2014) (0)
- Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer. (2021) (0)
- In vivo active-targeting fluorescence molecular imaging with adaptive background fluorescence subtraction (2023) (0)
- EP-1932: Assessment of Specific versus Combined Model Library in Knowledge Based Planning for Prostate Cancer (2018) (0)
- Assessment of biochemical disease free progression in men with prostate cancer younger than 60 years of age :MD Anderson experience (2001) (0)
- Escalated Dose Painting of DCE-MRI Defined Regions of High Tumor Burden in Prostate Cancer (2011) (0)
- MP09-01 GENOMIC HETEROGENEITY IN TISSUE-BASED PROGNOSTIC SIGNATURES FROM PROSTATE BIOPSIES; RESULTS FROM TWO PROSPECTIVE TRIALS (2020) (0)
- 4-1BB Aptamer-Based Immunomodulation Enhances the Efficacy of Ionizing Radiation in a Preclinical Murine Tumor Model (2014) (0)
- COMMENT ON DOSE ESCALATION AND BIOCHEMICAL FAILURE IN PROSTATE CANCER : IN REGARD TO KUBAN ET AL. (INT J RADIA T ONCOL BIOL PHYS 2008;70:67-74). Authors' reply (2008) (0)
- Abstract LB-359: Effects of space time fractionated radiation on normal tissue toxicity (2011) (0)
- The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer. (2021) (0)
- TH‐D‐M100F‐06: Surface Smoothing of a Tubular Structure Using a Non‐Shrinking Algorithm (2007) (0)
- An Analysis of PTV Margins for Postoperative Pelvic Nodal Radiotherapy (PNRT) Using a Dose Accumulation Workflow (2022) (0)
- Chapter 28 – The Prostate (2010) (0)
- Initial management of high risk early stage prostate cancer: Radiation (2008) (0)
- Radiation Dose Escalation Reduces Distant Metastasis and Increases Survival for Men with Prostate Cancer: 10:22 PM (28) (2002) (0)
- Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon. (1995) (0)
- Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. (2010) (0)
- Results of a quality of life questionnaire two and three years after external beam radiotherapy for prostate cancer in a randomized dose escalation study (2001) (0)
- MO-DE-207B-02: Assessment and Localization of Aggressiveness in Prostate Cancer Using Dynamic Contrast Enhanced-MRI. (2016) (0)
- TU‐EE‐A4‐03: Daily Localization of Post‐Prostatectomy Patients with Combined CT and US Image Guidance (2005) (0)
- HIDRATE-PRO: A prospective pilot study evaluating a digital behavioral health intervention to improve bladder-filling compliance in patients with prostate cancer receiving radiation. (2023) (0)
- Abstract LB065: Prostate cancer molecular immunophenotypes in biopsies with high vs average radiation sensitivity as predicted by post-operative radiation therapy outcomes (PORTOS) scores (2021) (0)
- MDM2 as a predictor of prostate cancer outcome: An analysis of RTOG 8610 (2004) (0)
- Clinicogenomic characterization of prostate cancer liver metastases (2022) (0)
- Using Radiogenomics to Characterize MRI-Guided Prostate Cancer Biopsy Habitats (2015) (0)
- Preclinical Studies of a Novel Small Molecule Radiosensitizer of Prostate Cancer (2009) (0)
- Abstract PO-004: Intra-individual heterogeneity of prostate cancer gene expression signatures of luminal and basal subtypes: Implications for selection of biopsy cores for genomic testing (2020) (0)
- Image Guided Radiation Therapy for Prostate IMRT: Rectum Volume Changes and Dosimetric Considerations (2005) (0)
- Evaluation of Ki-67 Expression as an Independent Biomarker of Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer (2008) (0)
- Using hormone therapy with salvage radiotherapy according to presalvage PSA levels (2020) (0)
- The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT (2010) (0)
- 1014 PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy (1995) (0)
- Decision points and results of radiotherapy by prostate cancer risk group (2011) (0)
- Space-time Fractionation (STF): A Special Concept Whose Time Has Come (2011) (0)
- Contrasting Circulating Tumor Cells and Free Circulating DNA Responses in Men Treated for Prostate Cancer after Primary Versus Salvage Radiotherapy (2020) (0)
- 1065: Quality of Life among Men with Localized Prostate Cancer: A Two-Year Longitudinal Assessment (2004) (0)
- Correlation Between MRI-Derived Quantitative Biomarkers and Circulating Tumor Cells in Prostate Cancer (2015) (0)
- Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors (2019) (0)
- Personalized Medicine and Imaging A Tissue Biomarker – Based Model That Identi fi es Patients with a High Risk of Distant Metastasis and Differential Survival by Length of AndrogenDeprivation Therapy in RTOG Protocol 92-02 (2014) (0)
- Abstract 904: Podocyte-specific SMPDl3b modulates radiation-induced renal dysfunction (2017) (0)
- Model-based prediction of biochemical failure in prostate cancer patients following radiation therapy (2002) (0)
- Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence (2023) (0)
- Long-term patient reported outcomes from a phase III randomized prospective trial of conventional versus hypofractionated radiotherapy for localized prostate cancer (2017) (0)
- 1126 : Antisense MDM2 Oligonucleotides Sensitize Androgen-Insensitive Human Prostate Cancer Cells To Androgen Deprivation In Vitro And In Vivo (2006) (0)
- Use of multiparameter flow cytometric analysis in a short-term chemosensitivity assay (1986) (0)
- SU‐GG‐T‐424: Volume‐Based Isoeffective Dose Calculations for Hypofractionation and the Analysis of Critical Structure Limits with Respect to Known Toxicity Frequencies (2008) (0)
- Synergistic Prostate Cancer Targeted Radiosensitization by Gold Nanoparticles and Histone Deacetylase Inhibitor Romidepsin (2022) (0)
- Multi-fold Radiotherapy Technique (2010) (0)
- Local treatment for prostate cancer: 90 years later--response to M. V. Pilepich. (1995) (0)
- SU‐FF‐J‐60: Daily Localization for Prostate Bed Patients Based On Surgical Clips (2007) (0)
- Post-Treatment PSA Nadir as an Independent Predictor of Distant Metastasis Following Radiotherapy for Prostate Cancer: 10:29 AM (29) (2002) (0)
- DELINEATION AND VISUALIZATION OF PROSTATE CANCER FOR TARGETED RADIATION THERAPY ( RT ) (2009) (0)
- The use of prostate biopsy laterality results in localized prostate cancer does not predict for 7-yr bNED outcome (2002) (0)
- Pretreatment PSA Best Predictor of Radiotherapy Failure (1997) (0)
- A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry (2012) (0)
- Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. (2022) (0)
- Automatic Detection of Prostate Tumor Habitats using Diffusion MRI (2018) (0)
- SU‐FF‐J‐37: Comparison Between CT‐Based and Ultrasound‐Based Localization for Prostate Patients (2006) (0)
- Early Prostate Cancer (T1–2N0M0) (2015) (0)
- A Patient-Centric, Systematic, Quantitative, and Visual Approach to Prostate Cancer Treatment Decision Making (2019) (0)
- Abstract PR04: Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men (2017) (0)
- Gains from Real-time Prostate Motion Monitoring during External Beam Radiation Therapy (2008) (0)
- Enhancement of 3H-Docetaxel Delivery in Prostate Tumor In Vivo using MR-guided Focused Ultrasound (2009) (0)
- PCN25 CASE-MATCHED CONTROLLED STUDY SHOWS MEN PREFER PROSTATE BRACHYTHERAPY TO CONFORMAL RADIATION THERAPY (2004) (0)
- Poster Viewing PresentationMR Guided Focused Ultrasound for Cancer Therapy: Enhancement of Drug Delivery in Prostate Tumor In Vivo (2008) (0)
- Are there any prostate cancer patients without high risk features who need long term androgen deprivation with external beam radiation therapy? a recursive partitioning analysis (2004) (0)
- Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial (2012) (0)
- Increasing Role of Functional MRI as Decision Making Tool in Management of Prostate Cancer Patients on Active Surveillance (2012) (0)
- COX-2 Expression Does Not Predict Biochemical Failure in Patients Treated with Salvage Radiation Therapy for Prostate Cancer (2011) (0)
- 2034 Adenoviral-mediated E2F-1 expression sensitizes prostate cancer cells in vitro to ionizing radiation (1999) (0)
- SU‐GG‐I‐143: An in Vivo Study on the Enhancement of Gene Therapy with MR‐Guided Focused Ultrasound (MRgFUS) (2010) (0)
- Deep Learning Approach for Multi-Reference Tissue Normalization on T2-weighted MRI in Longitudinal Dataset from Prospective Radiotherapy Trial for Prostate Cancer (2020) (0)
- 1125 : Antisense MDM2 Sensitizes Prostate Tumors to Radiation Therapy and Androgen Deprivation in vivo (2006) (0)
- Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation via Manipulation of the MDM2 Pathway (2005) (0)
- Age: Does it matter in the selection of treatment for men with early-stage prostate cancer? (2006) (0)
- Stat3 as a correlate of distant metastasis in RTOG 86–10 (2005) (0)
- Hormone Sensitivity of the R 3327-G Rat Prostate Adenocarcinoma : Growth Rate , DMA Content , and Hormone Receptors 1 (2006) (0)
- SU‐GG‐I‐139: Synergetic Effect of Docetaxel and MR Guided Focused Ultrasound (MRgFUS) for Prostate Cancer (2010) (0)
- Association of Circulating Tumor Cells (CTCs) and Genomic Signatures in Prostate Cancer Patients (2018) (0)
- Chapter 10 – Prostate Cancer Prevention: Strategies and Realities (2003) (0)
- Advanced prostate cancer and postoperative radiotherapy. Authors' reply (2007) (0)
- Abstract 5327: In vivo fluorescence imaging of solid tumor-bisphosphonate interaction (2011) (0)
- 2187 : Adenoviral E2F1 and Antisense MDM2 Sensitize Prostate Cancer Cells To Androgen Deprivation and Radiation (2006) (0)
- The Phoenix Definition of Biochemical Failure Correlates With Clinical Failure for Men Treated With Adjuvant and Salvage Post-Prostatectomy Radiation: Results of the Multi-institutional Pooled Analysis (2007) (0)
- Assessment of IMPT versus VMAT plans using different uncertainty scenarios for prostate cancer (2022) (0)
- Abstract 4183: Recruiting African-American prostate cancer patients for biobank research (2019) (0)
- Abstract 3516: Commercial gene expression tests for prostate cancer outcome risk in men of West African ancestry (2020) (0)
- 1136: Which Definition of Biochemical Failure after Post-Operative Radiotherapy Predicts Best for Clinical Failure? A Multi-Institutional Analysis (2005) (0)
- Clinical-genomic Risk Group Classification of Suspicions Lesions on Prostate mpMRI (2019) (0)
- CMR-4548-Validation of the cell cycle G2 delay assay in (2009) (0)
- 1139 Effect of preoperative radiotherapy on clinical-to-pathologic downstaging in muscle-invasive bladder cancer (1995) (0)
- PCN24 QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING (2010) (0)
- Issues in the management of locally advanced prostate cancer (1998) (0)
- Radiation dose requirements for favorable risk prostate cancer subgroups using recursive partitioning (2002) (0)
- Definitive Chemoradiotherapy for Locally Advanced Oropharyngeal Cancer: A Comparison of 3D-CRT vs. IMRT (2009) (0)
- Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (0)
- 106 : Comparison of Outcomes in Low Risk Prostate Cancer: I-125 Seed Brachytherapy vs. Intensity Modulated Radiotherapy (2006) (0)
- Male Sexual Dysfunction Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer (2012) (0)
- WE‐D‐BRA‐04: Problems Associated with IMRT Combined with a Single Fraction, 4D, High Dose Partial Prostate Boost (2007) (0)
- Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10) (2022) (0)
- The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy – Authors’ reply (2022) (0)
- MO‐E‐351‐01: MRI Simulation for Prostate Cancer (2008) (0)
- MP27-12 DEVELOPMENT OF EXOSOME-BASED PLASMA RNA BIOMARKERS FOR HIGH-RISK PROSTATE CANCER (2022) (0)
- Lymphocyte Suppression in Heart Transplant Recipients after Thymoglobulin Dosing Based on CD3+ Lymphocyte Counts. (2020) (0)
- Dose Response for Salvage Radiation Therapy After Radical Prostatectomy in Margin-Positive Prostate Cancer (2015) (0)
- Oral Scientific SessionsMulti-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features (2017) (0)
- SU‐FF‐T‐386: Treatment Optimization for Prostate IMRT Incorporating Utility Analysis and Patient Decisions (2005) (0)
- Intensity Modulated Radiation Therapy To Reduce Dose to Erectile Tissue during Prostate Cancer Treatment: P026 (2003) (0)
- Radiation-Mediated Inhibition of IFN Signaling Sensitizes VSV Resistant Prostate Cancer Cells (2014) (0)
- Joint Symposium Room : Monarch Breast Cancer Imaging and Treatment SAA-Monarch-01 Radiation Therapy in the Management of Early Stage Breast Cancer (2009) (0)
- MP55-05 BASELINE 4K SCORE PREDICTS PROGRESSION ON ACTIVE SURVEILLANCE IN PROSTATE CANCER INDEPENDENTLY OF CLINICAL INFORMATION AND PIRADS SCORE (2023) (0)
- Exploring Heterogeneity Within Hispanic/Latino Men Diagnosed With Prostate Cancer to Identify at-Risk US Populations (2016) (0)
- The Molecular Mechanism of the Supra-Additive Response of Prostate Cancer to Androgen Ablation and Radiotherapy. (2001) (0)
- SP-0706 Pelvic nodal irradiation or no nodal pelvic irradiation in prostate cancer, that is the question (2021) (0)
- Temporal Changes of Circulating Tumor Cells in Prostate Cancer Patients after Radiation Therapy (2020) (0)
- Defining Long Term Failure Risk in Patients With an Undetectable PSA After Salvage Radiation (2014) (0)
- A commentary on: Dose escalation and bned in prostate cancer. Authors' reply (2003) (0)
- In regard to Sherertz et al., IJROBP 2001; 51:1241-1245. (2002) (0)
- Three Dimensional Conformal Radiation as Adjuvant and Salvage Therapy after Prostatectomy: P-26 (2002) (0)
- Identification of Hypoxic Regions In Vivo in the Prostate (2009) (0)
- Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer (2013) (0)
- Interactions of Urea-Based Inhibitors with Prostate-Specific Membrane Antigen for Boron Neutron Capture Therapy (2021) (0)
- Real time data collection: improving prostate cancer research (2016) (0)
- Protein Kinase A RI-α Overexpression is Associated with Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy: A Secondary Analysis of RTOG 92-02 (2008) (0)
- SU‐E‐U‐01: MR Guided Pulsed High Intensity Focused Ultrasound Enhancement of Chemotherapy for Prostate Cancer (2011) (0)
- Dosimetry and Toxicity of a Phase I Clinical Trial of Men Treated for Prostate Cancer with Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (2018) (0)
- Automated Prostate Bed Lesion Detection: The Next Step in Salvage Radiation Therapy Dose Escalation (2014) (0)
- Does Hyperinsulinemia in Type-II Diabetes Mellitus Influence Disease Presentation and Long-Term Treatment Outcomes of Localized Prostate Cancer? (2005) (0)
- Molecular Profiling in the Practice of Radiation Oncology. (2017) (0)
- SU‐GG‐J‐133: MR Guided Focused Ultrasound (MRgFU) for Cance Therapy (2008) (0)
- Long-Term O utcome o f P atients W ith A merican J oint Committee o n C ancer S tage I IB E xtremity Soft T issue S arcomas (1999) (0)
- A Biomarker Panel Associated With Distant Metastasis (DM) in Prostate Cancer Patients Treated With Radiation Therapy Is Also Prognostic for DM in a Large Cohort of Prostatectomy Patients (2015) (0)
- Linked Dual Nomograms That Consider Radiation Dose and Length of Androgen Deprivation in the Estimation of Biochemical Failure at Five Years (2011) (0)
- Does a Delay in Low Dose Rate (LDR) Brachytherapy After Tissue Diagnosis Affect Outcome for Men with Low Risk Prostate Cancer (2005) (0)
- WE‐E‐220‐07: Therapeutic Effects of Pulsed Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy on Prostate Cancer In Vivo (2011) (0)
- SU-D-207A-03: Potential Role of BOLD MRI in Discrimination of Aggressive Tumor Habitat in Prostate Cancer. (2016) (0)
- A meta-analysis of health-related quality of life after primary treatment for prostate cancer as measured by the Expanded Prostate Cancer Index Composite. (2015) (0)
- Comment on: Erectile dysfunction and radiation dose to penile base structures: A lack of correlation. Authors' reply (2004) (0)
- Oral Scientific SessionsLong-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men With Clinically Localized Prostate Cancer (2017) (0)
- Dynamic Contrast Enhanced MRI for the Identification of Prostate Cancer in the Prostate Bed After Radical Prostatectomy (2011) (0)
- Therapeutic Effects of Edelfosine with Androgen Deprivation in Androgen Sensitive Prostate Cancer Cells In Vitro and In Vivo (2008) (0)
- PO-0908: Identification of a single nucleotide polymorphism associated with sexual dysfunction in prostate cancer patients (2013) (0)
- Estimating Gains in Biochemical Outcome from Various Durations of Androgen Deprivation in Patients Treated with Dose Escalated Radiotherapy for Prostate Cancer using Two Nomograms (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Allan P. Pollack?
Allan P. Pollack is affiliated with the following schools:
